Subscribe To
APLS / Apellis Pharmaceuticals, Inc. (APLS) Moves 16.3% Higher: Will This Strength Last?
APLS News
By Zacks Investment Research
November 2, 2023
Apellis (APLS) Q3 Loss Wider Than Expected, Syfovre Drives Sales
Apellis' (APLS) third-quarter 2023 bottom line misses estimates, while the top line beats the same. Newly approved product, Syfovre, drives sales in t more_horizontal
By Seeking Alpha
November 1, 2023
Apellis Pharmaceuticals, Inc. (APLS) Q3 2023 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q3 2023 Earnings Conference Call November 1, 2023 8:00 AM ET Company Participants Cedric Francois - Co-Fo more_horizontal
By Zacks Investment Research
November 1, 2023
Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Tops Revenue Estimates
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $0.84. This co more_horizontal
By GlobeNewsWire
October 25, 2023
Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results
WALTHAM, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conferen more_horizontal
By Zacks Investment Research
October 24, 2023
New Strong Buy Stocks for October 24th
MFA, GFF, OPI, APLS and GRPN have been added to the Zacks Rank #1 (Strong Buy) List on October 24, 2023. more_horizontal
By Schaeffers Research
October 6, 2023
Pharma Stock Upgraded on Eye Disorder Drug Sales
Apellis Pharmaceuticals Inc (NASDAQ:APLS) stock is enjoying a boost today after an upgrade from J.P. more_horizontal
By Yahoo Finance
October 6, 2023
Trending stocks October 6, 2023: E.l.f. Beauty, Apellis Pharma, AutoZone:
Stocks take in the morning's September jobs report data. e.l.f. Beauty (ELF) shares tick up this morning following an upgrade to "Buy" from Jefferies more_horizontal
By The Motley Fool
September 27, 2023
Why Shares of Apellis Pharmaceuticals Were Down Wednesday
Apellis just got a J-code for reimbursement for its lead therapy from CMS. The company saw revenue climb 473% year over year in the second quarter. more_horizontal